TOP TEN perturbations for 1298_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1298_at
Selected probe(set): 205225_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1298_at (205225_at) across 6672 perturbations tested by GENEVESTIGATOR:

ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) / ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary)

Relative Expression (log2-ratio):8.152136
Number of Samples:2 / 2
Experimental ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary transitional cell carcinoma, NOS of the ovary (subcutaneously implanted).
Control ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenocarcinoma, NOS of the ovary (subcutaneously implanted).

ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) / ovarian tumor study 30 (PDX; mixed tumor, malignant, NOS; primary)

Relative Expression (log2-ratio):7.3832455
Number of Samples:2 / 2
Experimental ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary transitional cell carcinoma, NOS of the ovary (subcutaneously implanted).
Control ovarian tumor study 30 (PDX; mixed tumor, malignant, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary mixed tumor, malignant, NOS of the ovary (subcutaneously implanted).

ovarian tumor study 30 (PDX; serous cystadenocarcinoma, NOS; primary) / ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary)

Relative Expression (log2-ratio):7.0524483
Number of Samples:13 / 2
Experimental ovarian tumor study 30 (PDX; serous cystadenocarcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary serous cystadenocarcinoma, NOS of the ovary (subcutaneously implanted).
Control ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenocarcinoma, NOS of the ovary (subcutaneously implanted).

ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) / ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary)

Relative Expression (log2-ratio):6.9781237
Number of Samples:2 / 2
Experimental ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary transitional cell carcinoma, NOS of the ovary (subcutaneously implanted).
Control ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary clear cell adenocarcinoma, NOS of the ovary (subcutaneously implanted).

ovarian tumor study 30 (PDX; serous cystadenocarcinoma, NOS; primary) / ovarian tumor study 30 (PDX; mixed tumor, malignant, NOS; primary)

Relative Expression (log2-ratio):6.283558
Number of Samples:13 / 2
Experimental ovarian tumor study 30 (PDX; serous cystadenocarcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary serous cystadenocarcinoma, NOS of the ovary (subcutaneously implanted).
Control ovarian tumor study 30 (PDX; mixed tumor, malignant, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary mixed tumor, malignant, NOS of the ovary (subcutaneously implanted).

breast cancer study 53 (ER+/PR+/HER2-; reference) / breast cancer study 53 (TNBC; reference)

Relative Expression (log2-ratio):5.915373
Number of Samples:31 / 14
Experimental breast cancer study 53 (ER+/PR+/HER2-; reference)
Primary tumor tissue samples obtained from patients with breast carcinoma grade I-III expressing estrogen (ER+) and progesterone receptors (PR+) and lacking HER2/Neu (HER2-); reference set of tumor.
Control breast cancer study 53 (TNBC; reference)
Primary tumor tissue samples obtained from patients with breast carcinoma grade I-III lacking estrogen (ER-) and progesterone receptors (PR-) and HER2/Neu (HER2-); triple negative breast cancer (TNBC) reference set of tumor.

expO breast cancer study 1 (papillary carcinoma, NOS; primary) / expO breast cancer study 1 (adenocarcinoma with squamous metaplasia; primary)

Relative Expression (log2-ratio):5.8891497
Number of Samples:2 / 2
Experimental expO breast cancer study 1 (papillary carcinoma, NOS; primary)
Primary tumor tissue samples obtained from the breast of patients with papillary carcinoma (NOS).
Control expO breast cancer study 1 (adenocarcinoma with squamous metaplasia; primary)
Primary tumor tissue samples obtained from the breast of patients with adenocarcinoma with squamous metaplasia.

ovarian tumor study 30 (PDX; serous cystadenocarcinoma, NOS; primary) / ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary)

Relative Expression (log2-ratio):5.878436
Number of Samples:13 / 2
Experimental ovarian tumor study 30 (PDX; serous cystadenocarcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary serous cystadenocarcinoma, NOS of the ovary (subcutaneously implanted).
Control ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary clear cell adenocarcinoma, NOS of the ovary (subcutaneously implanted).

breast cancer study 50 (subtype V) / breast cancer study 50 (subtype I)

Relative Expression (log2-ratio):5.8190727
Number of Samples:41 / 37
Experimental breast cancer study 50 (subtype V)
Primary tumor tissue samples obtained from the breast of patients with breast cancer with KFSYSCC subtype V. Samples were collected at the Koo Foundation Sun-Yat-Sen Cancer Center (KFSYSCC) between 1991 and 2004. Exclusion criteria: patients with follow-up periods shorter than three years, with the exception of patients who died of the disease within three years of the initial treatment. KFSYSCC subtype V:predominantly positive for ER, predominantly positive for PR, predominantly negative for HER2, long-term survival with hormonal therapy alone following surgery and/or radiation therapy, adjuvant chemotherapy did not provide any survival benefit in early stages, consistent with a unique subset of luminal A intrinsic type, smaller tumors dominate (T-stage), least likely to metastasize, increased expressions of cell cycle/proliferation genes, low risk of distant recurrence
Control breast cancer study 50 (subtype I)
Primary tumor tissue samples obtained from the breast of patients with breast cancer with KFSYSCC subtype I. Samples were collected at the Koo Foundation Sun-Yat-Sen Cancer Center (KFSYSCC) between 1991 and 2004. Exclusion criteria: patients with follow-up periods shorter than three years, with the exception of patients who died of the disease within three years of the initial treatment. KFSYSCC subtype I:predominantly negative for ER, variable for PR expression, predominantly negative for HER2, in concordance with chemosensitive basal-like intrinsic type, CMF yielded survival outcome similar to those of CAF, increased expressions of cell cycle/proliferation genes, high risk of distant recurrence

breast cancer study 53 (ER+/PR+/HER2-; reference) / breast cancer study 53 (ER-/PR-; reference)

Relative Expression (log2-ratio):5.615197
Number of Samples:31 / 2
Experimental breast cancer study 53 (ER+/PR+/HER2-; reference)
Primary tumor tissue samples obtained from patients with breast carcinoma grade I-III expressing estrogen (ER+) and progesterone receptors (PR+) and lacking HER2/Neu (HER2-); reference set of tumor.
Control breast cancer study 53 (ER-/PR-; reference)
Primary tumor tissue samples obtained from patients with breast carcinoma grade I-III lacking estrogen (ER-) and progesterone receptors (PR-); reference set of tumor.